MeiraGTx Holdings plc (NASDAQ:MGTX) Stake Raised by Royce & Associates LP

Royce & Associates LP increased its holdings in MeiraGTx Holdings plc (NASDAQ:MGTX) by 5.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 795,392 shares of the company’s stock after buying an additional 40,000 shares during the quarter. Royce & Associates LP’s holdings in MeiraGTx were worth $3,317,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its position in MeiraGTx by 14.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 462,950 shares of the company’s stock worth $1,949,000 after acquiring an additional 58,854 shares during the period. Vanguard Group Inc. lifted its holdings in MeiraGTx by 3.7% in the first quarter. Vanguard Group Inc. now owns 323,891 shares of the company’s stock worth $1,966,000 after purchasing an additional 11,470 shares during the period. Privium Fund Management B.V. lifted its holdings in MeiraGTx by 4.9% in the third quarter. Privium Fund Management B.V. now owns 213,960 shares of the company’s stock worth $892,000 after purchasing an additional 10,000 shares during the period. Russell Investments Group Ltd. grew its position in MeiraGTx by 1.9% in the 1st quarter. Russell Investments Group Ltd. now owns 157,999 shares of the company’s stock valued at $959,000 after buying an additional 2,994 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in MeiraGTx by 10.8% during the 2nd quarter. Rhumbline Advisers now owns 52,996 shares of the company’s stock valued at $223,000 after buying an additional 5,178 shares during the period. 67.48% of the stock is currently owned by institutional investors and hedge funds.

MeiraGTx Price Performance

Shares of MeiraGTx stock opened at $6.09 on Tuesday. MeiraGTx Holdings plc has a 52 week low of $3.85 and a 52 week high of $7.60. The company has a current ratio of 2.34, a quick ratio of 2.36 and a debt-to-equity ratio of 0.86. The company’s 50-day moving average price is $5.17 and its two-hundred day moving average price is $4.80. The stock has a market cap of $475.95 million, a PE ratio of -5.03 and a beta of 1.24.

Wall Street Analysts Forecast Growth

MGTX has been the subject of several recent analyst reports. Chardan Capital reiterated a “buy” rating and issued a $36.00 price objective on shares of MeiraGTx in a report on Monday. Royal Bank of Canada increased their price target on MeiraGTx from $9.00 to $11.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.